Breaking News

Tuesday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Earnings
Gamida Cell reports Q2 EPS (37c), consensus (30c) » 08:12
08/11/20
08/11
08:12
08/11/20
08:12
GMDA

Gamida Cell

$4.20 /

-0.005 (-0.12%)

"The primary…

"The primary endpoint data for omidubicel underscore its potential to become an important treatment option for patients by providing a reliable graft source that can enable rapid neutrophil engraftment, which has been linked to other important outcomes such as fewer infections and hospitalizations," stated Julian Adams, Ph.D., CEO of Gamida Cell. "We look forward to reporting secondary endpoints from the study and to initiating the biologics license application, or BLA, for omidubicel to the FDA on a rolling basis, both in the fourth quarter of this year."

ShowHide Related Items >><<
GMDA Gamida Cell
$4.20 /

-0.005 (-0.12%)

GMDA Gamida Cell
$4.20 /

-0.005 (-0.12%)

07/01/20
Fly Intel: Top five analyst initiations
06/30/20 Evercore ISI
Gamida Cell initiated with an Outperform at Evercore ISI
05/26/20
Fly Intel: Top five analyst initiations
05/25/20 Piper Sandler
Gamida Cell initiated with an Overweight at Piper Sandler
GMDA Gamida Cell
$4.20 /

-0.005 (-0.12%)

  • 19
    May
GMDA Gamida Cell
$4.20 /

-0.005 (-0.12%)

Over a week ago
Hot Stocks
Gamida Cell names Michele Korfin Chief Operating and Chief Commercial Officer » 08:18
07/21/20
07/21
08:18
07/21/20
08:18
GMDA

Gamida Cell

$4.43 /

-0.05 (-1.12%)

Gamida Cell announced the…

Gamida Cell announced the appointment of Michele Korfin as chief operating and chief commercial officer. Gamida Cell said in a release, "Ms. Korfin brings over 20 years of experience in oncology, focused on business operations and commercialization of novel therapies. In this role, she will have oversight of manufacturing and commercialization as Gamida Cell advances its clinical development candidates: omidubicel, an advanced cell therapy in Phase 3 clinical development as a potentially life-saving treatment option for patients in need of bone marrow transplant, and GDA-201, an investigational, natural killer cell-based cancer immunotherapy in Phase 1 development in patients with non-Hodgkin lymphoma. Prior to joining Gamida Cell, Ms. Korfin served as COO at TYME Technologies."

ShowHide Related Items >><<
GMDA Gamida Cell
$4.43 /

-0.05 (-1.12%)

GMDA Gamida Cell
$4.43 /

-0.05 (-1.12%)

07/01/20
Fly Intel: Top five analyst initiations
06/30/20 Evercore ISI
Gamida Cell initiated with an Outperform at Evercore ISI
05/26/20
Fly Intel: Top five analyst initiations
05/25/20 Piper Sandler
Gamida Cell initiated with an Overweight at Piper Sandler
GMDA Gamida Cell
$4.43 /

-0.05 (-1.12%)

  • 19
    May
GMDA Gamida Cell
$4.43 /

-0.05 (-1.12%)

Over a month ago
Initiation
Fly Intel: Top five analyst initiations » 10:05
07/01/20
07/01
10:05
07/01/20
10:05
PZZA

Papa John's

$80.96 /

+1.52 (+1.91%)

, DKNG

DraftKings

$34.10 /

+0.83 (+2.49%)

, WSC

WillScot Mobile Mini

$12.93 /

+0.64 (+5.21%)

, GMDA

Gamida Cell

$4.70 /

+0.15 (+3.30%)

, IHG

InterContinental

$45.30 /

+0.95 (+2.14%)

Catch up on today's…

Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Papa John's (PZZA) initiated with an Outperform at Wedbush. 2. DraftKings (DKNG) initiated with an Overweight at Stephens. 3. WillScot (WSC) initiated with a Buy at Stifel. 4. Gamida Cell (GMDA) initiated with an Outperform at Evercore ISI. 5. InterContinental (IHG) initiated with a Neutral at Credit Suisse. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.

ShowHide Related Items >><<
WSC WillScot Mobile Mini
$12.93 /

+0.64 (+5.21%)

PZZA Papa John's
$80.96 /

+1.52 (+1.91%)

IHG InterContinental
$45.30 /

+0.95 (+2.14%)

GMDA Gamida Cell
$4.70 /

+0.15 (+3.30%)

DKNG DraftKings
$34.10 /

+0.83 (+2.49%)

PZZA Papa John's
$80.96 /

+1.52 (+1.91%)

07/01/20 Wedbush
Wedbush bullish on Papa John's, initiates with an Outperform
06/30/20 Wedbush
Papa John's initiated with an Outperform at Wedbush
06/29/20 BTIG
Papa John's price target raised to $95 from $85 at BTIG
06/26/20 Stephens
Papa John's price target raised to $94 from $83 at Stephens
DKNG DraftKings
$34.10 /

+0.83 (+2.49%)

06/30/20 Stephens
Stephens starts DraftKings at Overweight amid U.S. gambling 'mega-trend'
06/30/20 Stephens
DraftKings initiated with an Overweight at Stephens
06/26/20
Fly Intel: Top five analyst initiations
06/25/20 Rosenblatt
DraftKings initiated with a Buy at Rosenblatt
WSC WillScot Mobile Mini
$12.93 /

+0.64 (+5.21%)

06/30/20 Stifel
WillScot initiated with a Buy at Stifel
05/28/20 BofA
WillScot resumed with a Buy at BofA
11/25/19 DA Davidson
WillScot price target raised to $23 from $20 at DA Davidson
09/26/19 Deutsche Bank
WillScot acquisition of Mobile Mini would be well received, says Deutsche Bank
GMDA Gamida Cell
$4.70 /

+0.15 (+3.30%)

06/30/20 Evercore ISI
Gamida Cell initiated with an Outperform at Evercore ISI
05/26/20
Fly Intel: Top five analyst initiations
05/25/20 Piper Sandler
Gamida Cell initiated with an Overweight at Piper Sandler
05/12/20 Oppenheimer
Gamida's omidubicel results 'potentially paradigm-changing,' says Oppenheimer
IHG InterContinental
$45.30 /

+0.95 (+2.14%)

07/01/20 Credit Suisse
InterContinental initiated with a Neutral at Credit Suisse
06/26/20 Peel Hunt
InterContinental initiated with a Buy at Peel Hunt
06/25/20 Jefferies
InterContinental downgraded to Hold from Buy at Jefferies
06/23/20 HSBC
InterContinental price target lowered to 4,400 GBp from 5,000 GBp at HSBC
WSC WillScot Mobile Mini
$12.93 /

+0.64 (+5.21%)

PZZA Papa John's
$80.96 /

+1.52 (+1.91%)

GMDA Gamida Cell
$4.70 /

+0.15 (+3.30%)

DKNG DraftKings
$34.10 /

+0.83 (+2.49%)

  • 19
    Jun
  • 19
    May
PZZA Papa John's
$80.96 /

+1.52 (+1.91%)

IHG InterContinental
$45.30 /

+0.95 (+2.14%)

DKNG DraftKings
$34.10 /

+0.83 (+2.49%)

PZZA Papa John's
$80.96 /

+1.52 (+1.91%)

IHG InterContinental
$45.30 /

+0.95 (+2.14%)

GMDA Gamida Cell
$4.70 /

+0.15 (+3.30%)

DKNG DraftKings
$34.10 /

+0.83 (+2.49%)

DKNG DraftKings
$34.10 /

+0.83 (+2.49%)

Initiation
Gamida Cell initiated with an Outperform at Evercore ISI » 16:29
06/30/20
06/30
16:29
06/30/20
16:29
GMDA

Gamida Cell

$4.55 /

+0.07 (+1.56%)

Evercore ISI analyst…

Evercore ISI analyst Jonathan Miller initiated coverage of Gamida Cell with an Outperform rating.

ShowHide Related Items >><<
GMDA Gamida Cell
$4.55 /

+0.07 (+1.56%)

GMDA Gamida Cell
$4.55 /

+0.07 (+1.56%)

05/26/20
Fly Intel: Top five analyst initiations
05/25/20 Piper Sandler
Gamida Cell initiated with an Overweight at Piper Sandler
05/12/20 Oppenheimer
Gamida's omidubicel results 'potentially paradigm-changing,' says Oppenheimer
05/12/20 Oppenheimer
Gamida Cell price target raised to $20 from $18 at Oppenheimer
GMDA Gamida Cell
$4.55 /

+0.07 (+1.56%)

  • 19
    May
GMDA Gamida Cell
$4.55 /

+0.07 (+1.56%)

Initiation
Fly Intel: Top five analyst initiations » 10:07
05/26/20
05/26
10:07
05/26/20
10:07
GMDA

Gamida Cell

$5.72 /

+0.47 (+8.95%)

, CGNX

Cognex

$63.35 /

+1.66 (+2.69%)

, PEGA

Pegasystems

$94.06 /

+2.105 (+2.29%)

, AMAT

Applied Materials

$56.11 /

+1.69 (+3.11%)

, DIOD

Diodes

$50.34 /

+2.43 (+5.07%)

Catch up on today's…

Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Gamida Cell (GMDA) initiated with an Overweight at Piper Sandler. 2. Cognex (CGNX) initiated with a Hold at HSBC. 3. Pegasystems (PEGA) initiated with a Buy at Goldman Sachs. 4. Applied Materials (AMAT) initiated with an Equal Weight at Barclays. 5. Diodes (DIOD) initiated with a Buy at Loop Capital. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.

ShowHide Related Items >><<
PEGA Pegasystems
$94.06 /

+2.105 (+2.29%)

GMDA Gamida Cell
$5.72 /

+0.47 (+8.95%)

DIOD Diodes
$50.34 /

+2.43 (+5.07%)

CGNX Cognex
$63.35 /

+1.66 (+2.69%)

AMAT Applied Materials
$56.11 /

+1.69 (+3.11%)

GMDA Gamida Cell
$5.72 /

+0.47 (+8.95%)

05/25/20 Piper Sandler
Gamida Cell initiated with an Overweight at Piper Sandler
05/12/20 Oppenheimer
Gamida's omidubicel results 'potentially paradigm-changing,' says Oppenheimer
05/12/20 Oppenheimer
Gamida Cell price target raised to $20 from $18 at Oppenheimer
04/27/20
Fly Intel: Top five analyst initiations
CGNX Cognex
$63.35 /

+1.66 (+2.69%)

05/25/20 HSBC
Cognex initiated with a Hold at HSBC
04/28/20 Raymond James
Cognex price target raised to $60 from $48 at Raymond James
03/23/20 Morgan Stanley
Morgan Stanley cuts Multi-Industry estimates, shakes up ratings with 7 changes
03/23/20 Morgan Stanley
Cognex downgraded to Underweight from Equal Weight at Morgan Stanley
PEGA Pegasystems
$94.06 /

+2.105 (+2.29%)

05/26/20 Goldman Sachs
Pegasystems initiated with a Buy at Goldman Sachs
04/30/20 Wedbush
Pegasystems price target raised to $104 from $96 at Wedbush
04/30/20 KeyBanc
Pegasystems price target lowered to $104 from $110 at KeyBanc
04/22/20 Wedbush
Pegasystems price target lowered to $96 from $103 at Wedbush
AMAT Applied Materials
$56.11 /

+1.69 (+3.11%)

05/26/20 Barclays
Applied Materials initiated with an Equal Weight at Barclays
05/15/20
Fly Intel: Top five analyst upgrades
05/15/20 DA Davidson
Applied Materials price target raised to $55 from $50 at DA Davidson
05/15/20 Needham
Applied Materials price target lowered to $70 from $73 at Needham
DIOD Diodes
$50.34 /

+2.43 (+5.07%)

05/26/20 Loop Capital
Diodes initiated with a Buy at Loop Capital
05/26/20 Loop Capital
Diodes initiated with a Buy at Loop Capital
05/21/20 Cowen
Diodes initiated with an Outperform at Cowen
04/17/20 Baird
Diodes upgraded to Outperform at Baird
PEGA Pegasystems
$94.06 /

+2.105 (+2.29%)

GMDA Gamida Cell
$5.72 /

+0.47 (+8.95%)

DIOD Diodes
$50.34 /

+2.43 (+5.07%)

CGNX Cognex
$63.35 /

+1.66 (+2.69%)

AMAT Applied Materials
$56.11 /

+1.69 (+3.11%)

AMAT Applied Materials
$56.11 /

+1.69 (+3.11%)

GMDA Gamida Cell
$5.72 /

+0.47 (+8.95%)

DIOD Diodes
$50.34 /

+2.43 (+5.07%)

CGNX Cognex
$63.35 /

+1.66 (+2.69%)

AMAT Applied Materials
$56.11 /

+1.69 (+3.11%)

AMAT Applied Materials
$56.11 /

+1.69 (+3.11%)

Initiation
Gamida Cell initiated with an Overweight at Piper Sandler » 18:25
05/25/20
05/25
18:25
05/25/20
18:25
GMDA

Gamida Cell

$5.25 /

+0.39 (+8.02%)

Piper Sandler analyst…

Piper Sandler analyst Edward Tenthoff initiated coverage of Gamida Cell with an Overweight rating and $13 price target. The analyst notes that Gamida Cell recently reported positive Phase III data on omidubicel for patients receiving hematopoietic stem cell transplant showing 10 days faster neutrophil engraftment than standard umbilical cord blood transplant. Gamida Cell plans to report full Phase III data and file a BLA later this year, he adds. Tenthoff expects FDA approval next year with U.S. sales reaching $468M by 2028. Gamida Cell recently issued 15.3M shares at $4.50 raising gross proceeds of $69M, bringing pro forma cash to about $105M, the analyst points out.

ShowHide Related Items >><<
GMDA Gamida Cell
$5.25 /

+0.39 (+8.02%)

GMDA Gamida Cell
$5.25 /

+0.39 (+8.02%)

05/12/20 Oppenheimer
Gamida's omidubicel results 'potentially paradigm-changing,' says Oppenheimer
05/12/20 Oppenheimer
Gamida Cell price target raised to $20 from $18 at Oppenheimer
04/27/20
Fly Intel: Top five analyst initiations
04/27/20 H.C. Wainwright
Gamida Cell initiated with a Buy at H.C. Wainwright
GMDA Gamida Cell
$5.25 /

+0.39 (+8.02%)

GMDA Gamida Cell
$5.25 /

+0.39 (+8.02%)

Hot Stocks
Gamida Cell sees FY20 cash used for ongoing operating activities $60M-$70M » 08:10
05/21/20
05/21
08:10
05/21/20
08:10
GMDA

Gamida Cell

$4.41 /

+0.02 (+0.46%)

Gamida Cell expects cash…

Gamida Cell expects cash used for ongoing operating activities in 2020 to range from $60M to $70M. Gamida Cell expects that, after accounting for the completion of its public follow-on offering, its current cash, cash equivalents and available-for-sale securities will support the company's ongoing operating activities into the second half of 2021. This cash runway guidance is based on the company's current operational plans and excludes any additional funding beyond the follow-on offering, or business development activities that may be undertaken.

ShowHide Related Items >><<
GMDA Gamida Cell
$4.41 /

+0.02 (+0.46%)

GMDA Gamida Cell
$4.41 /

+0.02 (+0.46%)

05/12/20 Oppenheimer
Gamida's omidubicel results 'potentially paradigm-changing,' says Oppenheimer
05/12/20 Oppenheimer
Gamida Cell price target raised to $20 from $18 at Oppenheimer
04/27/20
Fly Intel: Top five analyst initiations
04/27/20 H.C. Wainwright
Gamida Cell initiated with a Buy at H.C. Wainwright
GMDA Gamida Cell
$4.41 /

+0.02 (+0.46%)

  • 19
    May
GMDA Gamida Cell
$4.41 /

+0.02 (+0.46%)

Earnings
Gamida Cell reports Q1 EPS (31c), consensus (45c) » 08:09
05/21/20
05/21
08:09
05/21/20
08:09
GMDA

Gamida Cell

$4.41 /

+0.02 (+0.46%)

As of March 31, 2020,…

As of March 31, 2020, Gamida Cell had total cash, cash equivalents and available-for-sale securities of $40.3M, compared to $ 55.4M as of December 31, 2019. "Last week, we were extraordinarily pleased to report that our Phase 3 study of omidubicel met its primary endpoint of demonstrating a significant reduction in time to neutrophil engraftment, a key milestone in recovery from a bone marrow transplant. Shortening the time to engraftment is clinically meaningful, as it can reduce a patient's time in the hospital and decrease likelihood of infection. These positive study results represent an important step forward for Gamida Cell and the transplant community," stated Julian Adams, CEO of Gamida Cell. "Omidubicel is the first bone marrow transplant product to receive Breakthrough Therapy Designation from the U.S. FDA and has the potential to be the first FDA-approved bone marrow transplant graft. Our dedicated team is working hard to begin submitting the biologics license application for omidubicel to the FDA on a rolling basis in the fourth quarter."

ShowHide Related Items >><<
GMDA Gamida Cell
$4.41 /

+0.02 (+0.46%)

GMDA Gamida Cell
$4.41 /

+0.02 (+0.46%)

05/12/20 Oppenheimer
Gamida's omidubicel results 'potentially paradigm-changing,' says Oppenheimer
05/12/20 Oppenheimer
Gamida Cell price target raised to $20 from $18 at Oppenheimer
04/27/20
Fly Intel: Top five analyst initiations
04/27/20 H.C. Wainwright
Gamida Cell initiated with a Buy at H.C. Wainwright
  • 19
    May
GMDA Gamida Cell
$4.41 /

+0.02 (+0.46%)

On The Fly
Fly Intel: Pre-market Movers » 08:58
05/19/20
05/19
08:58
05/19/20
08:58
ABUS

Arbutus Biopharma

$1.85 /

-0.23 (-11.06%)

, WMT

Walmart

$127.66 /

+1.91 (+1.52%)

, AAP

Advance Auto Parts

$131.10 /

+5.09 (+4.04%)

, KSS

Kohl's

$18.86 /

+1.32 (+7.53%)

, WB

Weibo

$36.67 /

+1.57 (+4.47%)

, RADA

RADA Electronic

$4.43 /

+0.31 (+7.52%)

, HD

Home Depot

$244.59 /

+5.11 (+2.13%)

, MUX

McEwen Mining

$0.95 /

+0.0156 (+1.67%)

, IQ

iQIYI

$18.30 /

+0.33 (+1.84%)

, TMUS

T-Mobile

$101.89 /

+4.51 (+4.63%)

, MRNA

Moderna

$80.00 /

+13.3 (+19.94%)

, GMDA

Gamida Cell

$5.90 /

-0.45 (-7.09%)

Check out this morning's…

Open Full Text

ShowHide Related Items >><<
WMT Walmart
$127.66 /

+1.91 (+1.52%)

WB Weibo
$36.67 /

+1.57 (+4.47%)

TMUS T-Mobile
$101.89 /

+4.51 (+4.63%)

RADA RADA Electronic
$4.43 /

+0.31 (+7.52%)

MUX McEwen Mining
$0.95 /

+0.0156 (+1.67%)

MRNA Moderna
$80.00 /

+13.3 (+19.94%)

KSS Kohl's
$18.86 /

+1.32 (+7.53%)

IQ iQIYI
$18.30 /

+0.33 (+1.84%)

HD Home Depot
$244.59 /

+5.11 (+2.13%)

GMDA Gamida Cell
$5.90 /

-0.45 (-7.09%)

ABUS Arbutus Biopharma
$1.85 /

-0.23 (-11.06%)

AAP Advance Auto Parts
$131.10 /

+5.09 (+4.04%)

ABUS Arbutus Biopharma
$1.85 /

-0.23 (-11.06%)

05/19/20 Wedbush
Arbutus Biopharma upgraded to Outperform at Wedbush following AB-729 data
05/19/20 Wedbush
Arbutus Biopharma upgraded to Outperform from Neutral at Wedbush
03/06/20 Chardan
Chardan upgrades Arbutus to Buy, boosts target to $5 from $1.50
03/06/20 Chardan
Arbutus Biopharma upgraded to Buy from Neutral at Chardan
WMT Walmart
$127.66 /

+1.91 (+1.52%)

05/19/20 Stephens
Walmart's strong beat underscores durability of model, says Stephens
05/15/20 Jefferies
Target price target lowered to $111 from $121 at Jefferies
05/13/20 RBC Capital
Walmart price target raised to $129 from $126 at RBC Capital
04/29/20
Fly Intel: Top five analyst downgrades
AAP Advance Auto Parts
$131.10 /

+5.09 (+4.04%)

05/15/20 Cleveland Research
O'Reilly, AutoZone, Advance appear to be gaining share, says Cleveland Research
04/21/20
Fly Intel: Top five analyst upgrades
04/21/20 Guggenheim
Guggenheim raises two auto parts retailers, cuts one supplier in sector shake-up
04/21/20 Guggenheim
Advance Auto Parts upgraded to Buy from Neutral at Guggenheim
KSS Kohl's
$18.86 /

+1.32 (+7.53%)

05/07/20 Deutsche Bank
Kohl's price target lowered to $26 from $45 at Deutsche Bank
04/27/20 Guggenheim
Kohl's price target lowered to $25 from $50 at Guggenheim
03/27/20 Cleveland Research
Kohl's downgraded at Cleveland Research, says March-to-date comps down 50%
03/27/20 Cleveland Research
Kohl's downgraded to Underperform from Neutral at Cleveland Research
WB Weibo
$36.67 /

+1.57 (+4.47%)

05/06/20 OTR Global
Weibo downgraded to Negative from Mixed at OTR Global
04/22/20 Barclays
Weibo downgraded to Equal Weight from Overweight at Barclays
04/01/20
Weibo participates in a conference call with Benchmark
12/05/19 Goldman Sachs
Sina downgraded to Neutral from Buy at Goldman Sachs
RADA RADA Electronic
$4.43 /

+0.31 (+7.52%)

01/15/20
Fly Intel: Top five analyst initiations
01/15/20 Canaccord
RADA Electronic inflection expected in 2021, Canaccord initiates with Buy
01/15/20 Canaccord
RADA Electronic initiated with a Buy at Canaccord
09/19/19 Alliance Global Partners
RADA price target raised to $7.50 from $6.50 at Alliance Global Partners
HD Home Depot
$244.59 /

+5.11 (+2.13%)

05/19/20 Baird
Home Depot results strong but outlook suspended, says Baird
05/18/20 Baird
Home Depot price target raised to $265 from $215 at Baird
05/14/20 Cleveland Research
Homecenters had strong end of April, start to May, says Cleveland Research
05/12/20 Wells Fargo
Home Depot price target raised to $260 from $215 at Wells Fargo
MUX McEwen Mining
$0.95 /

+0.0156 (+1.67%)

09/10/19
Fly Intel: Top five analyst initiations
09/10/19 B. Riley FBR
B. Riley FBR starts McEwen Mining with Buy rating, $4.20 price target
09/10/19 B. Riley FBR
McEwen Mining initiated with a Buy at B. Riley FBR
IQ iQIYI
$18.30 /

+0.33 (+1.84%)

04/14/20
Fly Intel: Top five analyst initiations
04/13/20 Oppenheimer
iQIYI initiated with an Outperform at Oppenheimer
04/09/20 Mizuho
Baidu concerns overstated, current valuation 'compelling,' says Mizuho
02/28/20 CLSA
CLSA upgrades iQIYI to Outperform with coronavirus boosting traffic
TMUS T-Mobile
$101.89 /

+4.51 (+4.63%)

05/12/20 Citi
T-Mobile price target raised to $115 from $103 at Citi
05/07/20 JPMorgan
T-Mobile added to Analyst Focus List at JPMorgan
05/07/20 KeyBanc
T-Mobile price target raised to $104 from $99 at KeyBanc
05/07/20 Nomura Instinet
T-Mobile price target raised to $110 from $102 at Nomura Instinet
MRNA Moderna
$80.00 /

+13.3 (+19.94%)

05/19/20 BMO Capital
Moderna price target raised to $112 from $83 at BMO Capital
05/19/20 H.C. Wainwright
BioNTech upgraded to Buy from Neutral at H.C. Wainwright
05/18/20 Roth Capital
Moderna taking COVID-19 vaccine 'by the horns,' says Roth Capital
05/18/20 Oppenheimer
Moderna price target raised to $108 from $62 at Oppenheimer
GMDA Gamida Cell
$5.90 /

-0.45 (-7.09%)

05/12/20 Oppenheimer
Gamida's omidubicel results 'potentially paradigm-changing,' says Oppenheimer
05/12/20 Oppenheimer
Gamida Cell price target raised to $20 from $18 at Oppenheimer
04/27/20
Fly Intel: Top five analyst initiations
04/27/20 H.C. Wainwright
Gamida Cell initiated with a Buy at H.C. Wainwright
WMT Walmart
$127.66 /

+1.91 (+1.52%)

WB Weibo
$36.67 /

+1.57 (+4.47%)

TMUS T-Mobile
$101.89 /

+4.51 (+4.63%)

RADA RADA Electronic
$4.43 /

+0.31 (+7.52%)

MUX McEwen Mining
$0.95 /

+0.0156 (+1.67%)

MRNA Moderna
$80.00 /

+13.3 (+19.94%)

KSS Kohl's
$18.86 /

+1.32 (+7.53%)

IQ iQIYI
$18.30 /

+0.33 (+1.84%)

HD Home Depot
$244.59 /

+5.11 (+2.13%)

ABUS Arbutus Biopharma
$1.85 /

-0.23 (-11.06%)

AAP Advance Auto Parts
$131.10 /

+5.09 (+4.04%)

  • 19
    May
  • 19
    May
WMT Walmart
$127.66 /

+1.91 (+1.52%)

TMUS T-Mobile
$101.89 /

+4.51 (+4.63%)

MRNA Moderna
$80.00 /

+13.3 (+19.94%)

KSS Kohl's
$18.86 /

+1.32 (+7.53%)

IQ iQIYI
$18.30 /

+0.33 (+1.84%)

HD Home Depot
$244.59 /

+5.11 (+2.13%)

AAP Advance Auto Parts
$131.10 /

+5.09 (+4.04%)

WMT Walmart
$127.66 /

+1.91 (+1.52%)

TMUS T-Mobile
$101.89 /

+4.51 (+4.63%)

MUX McEwen Mining
$0.95 /

+0.0156 (+1.67%)

MRNA Moderna
$80.00 /

+13.3 (+19.94%)

KSS Kohl's
$18.86 /

+1.32 (+7.53%)

IQ iQIYI
$18.30 /

+0.33 (+1.84%)

HD Home Depot
$244.59 /

+5.11 (+2.13%)

ABUS Arbutus Biopharma
$1.85 /

-0.23 (-11.06%)

AAP Advance Auto Parts
$131.10 /

+5.09 (+4.04%)

WMT Walmart
$127.66 /

+1.91 (+1.52%)

WB Weibo
$36.67 /

+1.57 (+4.47%)

TMUS T-Mobile
$101.89 /

+4.51 (+4.63%)

MUX McEwen Mining
$0.95 /

+0.0156 (+1.67%)

MRNA Moderna
$80.00 /

+13.3 (+19.94%)

KSS Kohl's
$18.86 /

+1.32 (+7.53%)

IQ iQIYI
$18.30 /

+0.33 (+1.84%)

HD Home Depot
$244.59 /

+5.11 (+2.13%)

AAP Advance Auto Parts
$131.10 /

+5.09 (+4.04%)

Syndicate
Gamida Cell 13.333M share Spot Secondary priced at $4.50 » 06:01
05/19/20
05/19
06:01
05/19/20
06:01
GMDA

Gamida Cell

$5.90 /

-0.45 (-7.09%)

The deal range was…

The deal range was $4.50-$5.00. Piper Sandler and Evercore ISI acted as joint book running managers for the offering.

ShowHide Related Items >><<
GMDA Gamida Cell
$5.90 /

-0.45 (-7.09%)

GMDA Gamida Cell
$5.90 /

-0.45 (-7.09%)

05/12/20 Oppenheimer
Gamida's omidubicel results 'potentially paradigm-changing,' says Oppenheimer
05/12/20 Oppenheimer
Gamida Cell price target raised to $20 from $18 at Oppenheimer
04/27/20
Fly Intel: Top five analyst initiations
04/27/20 H.C. Wainwright
Gamida Cell initiated with a Buy at H.C. Wainwright
  • 19
    May
GMDA Gamida Cell
$5.90 /

-0.45 (-7.09%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.